These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25192810)

  • 21. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
    Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
    Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma and synovial fluid concentration of doxycycline following low-dose, low-frequency administration, and resultant inhibition of matrix metalloproteinase-13 from interleukin-stimulated equine synoviocytes.
    Maher MC; Schnabel LV; Cross JA; Papich MG; Divers TJ; Fortier LA
    Equine Vet J; 2014 Mar; 46(2):198-202. PubMed ID: 23855565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.
    Nicolotti O; Catto M; Giangreco I; Barletta M; Leonetti F; Stefanachi A; Pisani L; Cellamare S; Tortorella P; Loiodice F; Carotti A
    Eur J Med Chem; 2012 Dec; 58():368-76. PubMed ID: 23149299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
    Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship.
    Matter H; Schudok M; Schwab W; Thorwart W; Barbier D; Billen G; Haase B; Neises B; Weithmann K; Wollmann T
    Bioorg Med Chem; 2002 Nov; 10(11):3529-44. PubMed ID: 12213468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies.
    Nuti E; Cuffaro D; Bernardini E; Camodeca C; Panelli L; Chaves S; Ciccone L; Tepshi L; Vera L; Orlandini E; Nencetti S; Stura EA; Santos MA; Dive V; Rossello A
    J Med Chem; 2018 May; 61(10):4421-4435. PubMed ID: 29727184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In silico study combining docking and QSAR methods on a series of matrix metalloproteinase 13 inhibitors.
    Xi L; Li S; Yao X; Wei Y; Li J; Liu H; Wu X
    Arch Pharm (Weinheim); 2014 Nov; 347(11):825-33. PubMed ID: 25363411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-Zinc-Binding Inhibitors of MMP-13: GRID-Based Approaches to Rationalize the Binding Process.
    Di Pizio A; Agamennone M; Tortorella P
    Curr Top Med Chem; 2016; 16(4):449-59. PubMed ID: 26268339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors.
    Imaeda Y; Tawada M; Suzuki S; Tomimoto M; Kondo M; Tarui N; Sanada T; Kanagawa R; Snell G; Behnke CA; Kubo K; Kuroita T
    Bioorg Med Chem; 2016 Nov; 24(22):5771-5780. PubMed ID: 27687967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.
    Zhang J; Li X; Jiang Y; Feng J; Li X; Zhang Y; Xu W
    Bioorg Med Chem; 2014 Jun; 22(11):3055-64. PubMed ID: 24755524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3).
    Lum C; Kahl J; Kessler L; Kucharski J; Lundström J; Miller S; Nakanishi H; Pei Y; Pryor K; Roberts E; Sebo L; Sullivan R; Urban J; Wang Z
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3578-81. PubMed ID: 18502127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.
    Monovich LG; Tommasi RA; Fujimoto RA; Blancuzzi V; Clark K; Cornell WD; Doti R; Doughty J; Fang J; Farley D; Fitt J; Ganu V; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Parker DT; Melton R; O'Byrne E; Pastor G; Pellas T; Quadros E; Reel N; Roland DM; Sakane Y; Singh H; Skiles J; Somers J; Toscano K; Wigg A; Zhou S; Zhu L; Shieh WC; Xue S; McQuire LW
    J Med Chem; 2009 Jun; 52(11):3523-38. PubMed ID: 19422229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of potent and selective MMP-13 inhibitors.
    Wu J; Rush TS; Hotchandani R; Du X; Geck M; Collins E; Xu ZB; Skotnicki J; Levin JI; Lovering FE
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4105-9. PubMed ID: 16005220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y(12) antagonists for inhibition of platelet aggregation.
    Caroff E; Meyer E; Treiber A; Hilpert K; Riederer MA
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4323-31. PubMed ID: 25113932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Li JJ; Nahra J; Johnson AR; Bunker A; O'Brien P; Yue WS; Ortwine DF; Man CF; Baragi V; Kilgore K; Dyer RD; Han HK
    J Med Chem; 2008 Feb; 51(4):835-41. PubMed ID: 18251495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
    Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
    Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
    J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
    Spicer TP; Jiang J; Taylor AB; Choi JY; Hart PJ; Roush WR; Fields GB; Hodder PS; Minond D
    J Med Chem; 2014 Nov; 57(22):9598-611. PubMed ID: 25330343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
    Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
    J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
    Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
    Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.